| Arthritis, Psoriatic
Tremfya vs Xeljanz
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Tremfya vs Xeljanz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXeljanz has a higher rate of injection site reactions vs Tremfya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xeljanz but not Tremfya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tremfya
Xeljanz
At A Glance
Subcutaneous / Intravenous
Every 4-8 weeks
Interleukin-23 antagonist
Oral
Twice daily
JAK inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ulcerative Colitis
- Crohn Disease
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
- Juvenile polyarthritis
Dosing
Psoriasis vulgaris Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
Arthritis, Psoriatic Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD.
Ulcerative Colitis Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Crohn Disease Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).
Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.
Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.
Contraindications
- History of serious hypersensitivity reaction to guselkumab or to any of the excipients
—
Adverse Reactions
Most common (>=1%) Upper respiratory infections (14.3%), headache (4.6%), injection site reactions (4.5%), arthralgia (2.7%), diarrhea (1.6%), gastroenteritis (1.3%), tinea infections (1.1%), herpes simplex infections (1.1%).
Serious Serious infections occurred in <=0.2% in plaque psoriasis trials through Week 16. In ulcerative colitis trials, serious infections occurred in 0.8% with TREMFYA vs. 0% with placebo (44-week trial) and 1.8% vs. 0.7% (24-week trial). In Crohn's disease, serious infections occurred in 1.5% with TREMFYA vs. 0% with placebo.
Postmarketing Hypersensitivity including anaphylaxis, rash.
Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.
Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.
Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.
Pharmacology
Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines.
Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tremfya
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Xeljanz
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Tremfya
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (5/8)
Xeljanz
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Tremfya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Xeljanz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriatic Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Xeljanz.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TremfyaView full Tremfya profile
XeljanzView full Xeljanz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.